Stenocare（STENO）株式概要Stenocare A/S社は、処方箋に基づく医療用大麻製品の栽培、生産、輸入、流通、販売をデンマーク国内および国際的に行っている。 詳細STENO ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析キャッシュランウェイが1年未満である 過去5年間で収益は年間7.1%減少しました。 Danish市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( DKK46M )+1 さらなるリスクすべてのリスクチェックを見るSTENO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueDKK Current PriceDKK 1.1536.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-33m27m2016201920222025202620282031Revenue DKK 27.5mEarnings DKK 4.1mAdvancedSet Fair ValueView all narrativesStenocare A/S 競合他社BiotikaSymbol: BSSE:1BSL01AEMarket cap: €7.4mAvant BrandsSymbol: TSX:AVNTMarket cap: CA$9.0mInMed PharmaceuticalsSymbol: NasdaqCM:INMMarket cap: US$7.7mBiofronteraSymbol: NasdaqCM:BFRIMarket cap: US$9.5m価格と性能株価の高値、安値、推移の概要Stenocare過去の株価現在の株価DKK 1.1552週高値DKK 2.8052週安値DKK 0.40ベータ0.501ヶ月の変化5.99%3ヶ月変化-14.81%1年変化177.11%3年間の変化-85.06%5年間の変化-92.39%IPOからの変化-96.95%最新ニュースReported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: kr.3.00m (up 284% from 1Q 2025). Net loss: kr.459.0k (loss narrowed 77% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • May 08+ 3 more updatesStenocare A/S to Report Q2, 2026 Results on Aug 20, 2026Stenocare A/S announced that they will report Q2, 2026 results on Aug 20, 2026お知らせ • Apr 09Stenocare A/S, Annual General Meeting, Apr 29, 2026Stenocare A/S, Annual General Meeting, Apr 29, 2026, at 10:30 Romance Standard Time. Location: lund elmer sandager law firm, kalvebod brygge 39-41, dk-1560 kobenhavn v., DenmarkReported Earnings • Apr 01Full year 2025 earnings released: kr.0.06 loss per share (vs kr.1.79 loss in FY 2024)Full year 2025 results: kr.0.06 loss per share (improved from kr.1.79 loss in FY 2024). Revenue: kr.7.02m (up 215% from FY 2024). Net loss: kr.2.39m (loss narrowed 93% from FY 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 28Full year 2025 earnings released: kr.0.063 loss per share (vs kr.1.79 loss in FY 2024)Full year 2025 results: kr.0.063 loss per share (improved from kr.1.79 loss in FY 2024). Revenue: kr.7.02m (up 215% from FY 2024). Net loss: kr.2.39m (loss narrowed 93% from FY 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.New Risk • Dec 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr.62.2m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.3.4m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Revenue is less than US$1m (kr.5.7m revenue, or US$891k). Market cap is less than US$10m (kr.62.2m market cap, or US$9.77m).最新情報をもっと見るRecent updatesReported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: kr.3.00m (up 284% from 1Q 2025). Net loss: kr.459.0k (loss narrowed 77% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • May 08+ 3 more updatesStenocare A/S to Report Q2, 2026 Results on Aug 20, 2026Stenocare A/S announced that they will report Q2, 2026 results on Aug 20, 2026お知らせ • Apr 09Stenocare A/S, Annual General Meeting, Apr 29, 2026Stenocare A/S, Annual General Meeting, Apr 29, 2026, at 10:30 Romance Standard Time. Location: lund elmer sandager law firm, kalvebod brygge 39-41, dk-1560 kobenhavn v., DenmarkReported Earnings • Apr 01Full year 2025 earnings released: kr.0.06 loss per share (vs kr.1.79 loss in FY 2024)Full year 2025 results: kr.0.06 loss per share (improved from kr.1.79 loss in FY 2024). Revenue: kr.7.02m (up 215% from FY 2024). Net loss: kr.2.39m (loss narrowed 93% from FY 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 28Full year 2025 earnings released: kr.0.063 loss per share (vs kr.1.79 loss in FY 2024)Full year 2025 results: kr.0.063 loss per share (improved from kr.1.79 loss in FY 2024). Revenue: kr.7.02m (up 215% from FY 2024). Net loss: kr.2.39m (loss narrowed 93% from FY 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.New Risk • Dec 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr.62.2m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.3.4m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Revenue is less than US$1m (kr.5.7m revenue, or US$891k). Market cap is less than US$10m (kr.62.2m market cap, or US$9.77m).Reported Earnings • Oct 23Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr.103.3k (loss narrowed 98% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 27Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr.1.72m (up 131% from 2Q 2024). Net loss: kr.145.6k (loss narrowed 96% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.お知らせ • May 16Stenocare A/S Appoints Henrik Elbæk Pedersen as Board MemberStenocare A/S announced that at the AGM held on 15 May 2025 approved election of Henrik Elbæk Pedersen as a new board member. Hereafter, the board of directors consist of Marianne Wier (chairman), Jeppe Bo Petersen, Rolf Steno Petersen, Søren Melsing Frederiksen and Henrik Elbæk Pedersen.New Risk • May 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 110% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.7.0m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (110% increase in shares outstanding). Revenue is less than US$1m (kr.1.9m revenue, or US$279k). Market cap is less than US$10m (kr.13.8m market cap, or US$2.07m).Reported Earnings • May 09First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: kr.781.7k (down 32% from 1Q 2024). Net loss: kr.1.99m (loss narrowed 46% from 1Q 2024).お知らせ • Apr 23Stenocare A/S, Annual General Meeting, May 15, 2025Stenocare A/S, Annual General Meeting, May 15, 2025, at 10:00 Romance Standard Time. Location: lund elmer sandager law firm, kalvebod brygge 39-41, dk-1560, kobenhavn v, Denmarkお知らせ • Apr 03STENOCARE A/S and Its Local Partner Secure Approval for the Reimbursement of the Innovative Astrum 10-10 Product in GermanySTENOCARE A/S and its local partner have successfully secured approval for the reimbursement of the innovative ASTRUM 10-10 product by major German health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible for 100% reimbursement when treated with ASTRUM 10-10. The ASTRUM 10-10 oil product was made available to German patients in January 2025 and has now been approved for 100% reimbursement by two leading German health insurance providers, Techniker Krankenkasse and AOK Rheinland. Germany represents the largest medical cannabis market in Europe. Industry analysts, including Prohibition Partners, forecast a 275% growth by 2027, with total sales expected to reach EUR 1 billion. Stenocare's new and innovative medical cannabis oil product is officially named Astrum 10-10 Ext Stenocare. It contains 10 mg/ml of THC and 10 mg/ml of CBD, supplied in a 30 ml bottle. The PNZ is 15192488 and the German supplier is ADREXpharma GmbH. The Stenocare Astrum product is based on advanced oil technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation addresses a common challenge in medicinal dosing by promoting the consistent absorption of active ingredients. Stenocare has conducted a successful pharmacokinetic (PK) study in dogs, which demonstrated two key improvements in the lymphatic system that can significantly enhance bioavailability: A significant increase in cannabinoid uptake into the bloodstream, improving therapeutic effect and a faster, more uniform absorption across patients.Reported Earnings • Apr 02Full year 2024 earnings released: kr.1.79 loss per share (vs kr.1.26 loss in FY 2023)Full year 2024 results: kr.1.79 loss per share (further deteriorated from kr.1.26 loss in FY 2023). Revenue: kr.2.23m (down 41% from FY 2023). Net loss: kr.34.5m (loss widened 96% from FY 2023).お知らせ • Mar 31Stenocare Begins Sales of New CBD100 Oil Product in DenmarkSTENOCARE A/S has delivered the first shipment of its new CBD100 Oil product to the Danish market. With this new medical cannabis oil product, Stenocare now offers four different prescription-based medical cannabis oil products to Danish patients, making it the leading provider of oil products in the Danish Pilot Programme. The company already offers a THC30 Oil product, a CBD20 Oil product, and a THC/CBD Oil product. Now, Stenocare is adding its CBD100 Oil product to the portfolio-providing patients with even more treatment options and further strengthening its position as a leading provider of medical cannabis oil products in the Pilot Programme. The new product is named CBD100 Oil Stenocare, and it contains 100 mg/ml CBD and 5 mg/ml THC in a 30 ml bottle. The first shipment of CBD100 has just been delivered in Denmark and is now available to patients across the country.Reported Earnings • Feb 28Full year 2024 earnings released: kr.1.73 loss per share (vs kr.1.26 loss in FY 2023)Full year 2024 results: kr.1.73 loss per share (further deteriorated from kr.1.26 loss in FY 2023). Revenue: kr.2.23m (down 44% from FY 2023). Net loss: kr.34.5m (loss widened 96% from FY 2023).お知らせ • Feb 14Stenocare A/S Announces the Innovative Astrum 10-10 Product Is Now Available for Australian PatientsStenocare A/S reach an important milestone with ASTRUM 10-10, that is now ready for sales to Australian patients. The innovative and patented medical cannabis oil product, ASTRUM 10-10 has the potential to improve uptake in the blood and thereby improve efficacy of the treatment. Stenocare's new innovative medical cannabis oil product named Astrum 10-10 has been approved for sales in Australia and is now ready for patient's treatment. Officially named "Astrum 10-10 Oil Stenocare," the product contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle. The Stenocare Astrum product is based on cutting-edge oil technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation addresses a well-known challenge in medicine dosing by ensuring consistent uptake of active ingredients into the blood. With the Astrum product, Stenocare has successfully completed a pharmacokinetic (PK) study in dogs, documenting two critical parameters in the lymphatic system that can significantly improve bioavailability: Uptake in the Blood: According to the pharmacokinetic (PK) study in dogs, Astrum improves blood uptake by a factor of 2.6 compared to a reference MCT-oil product on the market. Low and inconsistent uptake of drugs in the blood across patients is a well-known challenge in the pharmaceutical industry, affecting most medications. This challenge also applies to medical cannabis. When patients use traditional MCT-oil-based medical cannabis, the metabolism often reduces the uptake of cannabinoids in the body. As a result, a highly variable and often limited amount of active ingredients (i.e., cannabinoids) reaches the patient with a therapeutic effect. This creates difficulties in prescribing a consistent dosage to patients. Additionally, blood uptake varies significantly from one individual to another due to biological differences. The new Astrum product helps mitigate these challenges by offering enhanced bioavailability.お知らせ • Jan 22Stenocare A/S has completed a Follow-on Equity Offering in the amount of DKK 9.095624 million.Stenocare A/S has completed a Follow-on Equity Offering in the amount of DKK 9.095624 million. Security Name: Shares Security Type: Common Stock Securities Offered: 18,191,248 Price\Range: DKK 0.5 Transaction Features: Rights Offeringお知らせ • Jan 03STENOCARE's Innovative ASTRUM 10-10 Product Now Available for Norwegian PatientsStenocare announced on December 2, 2024, that the new innovative medical cannabis oil product, named Astrum 10-10, has been approved for sale in Norway. At the end of December, the first shipment of this product arrived in Norway and is ready for patients' treatment. Officially named 'Astrum 10-10 Oil Stenocare,' the product contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle. The Stenocare Astrum product is based on cutting-edge oil technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation addresses a well-known challenge in medicine dosing by ensuring consistent uptake of active ingredients into the blood. With the Astrum product, Stenocare has successfully completed a pharmacokinetic (PK) study in dogs, documenting two critical parameters in the lymphatic system that can significantly improve bioavailability: Parameter 1 - Uptake in the Blood: According to the pharmacokinetic (PK) study in dogs, Astrum improves blood uptake by a factor of 2.6 compared to a reference MCT-oil product on the market. Low and inconsistent uptake of drugs in the blood across patients is a well-known challenge in the pharmaceutical industry, affecting most medications. This challenge also applies to medical cannabis. When patients use traditional MCT-oil-based medical cannabis, the metabolism often reduces the uptake of cannabinoids in the body. As a result, a highly variable and often limited amount of active ingredients (i.e., cannabinoids) reaches the patient with a therapeutic effect. This creates difficulties in prescribing a consistent dosage to patients. Additionally, blood uptake varies significantly from one individual to another due to biological differences. The new Astrum product helps mitigate these challenges by offering enhanced bioavailability. Parameter 2 - Time to Maximum Effect: According to the PK- study in dogs, the Stenocare Astrum product reduces the time from dosing to maximum effect from 2-4 hours to just 1 hour, providing a more consistent experience for patients. Predictability of uptake and time to maximum effect is crucial when doctors prescribe medical cannabis and when patients use it to treat their symptoms. Time to maximum effect refers to the duration it takes for the medication to reach its highest concentration in the blood after administration. Achieving this maximum effect as quickly as possible is important to help patients manage their symptoms effectively.お知らせ • Dec 20Stenocare A/S has filed a Follow-on Equity Offering in the amount of DKK 20.212497 million.Stenocare A/S has filed a Follow-on Equity Offering in the amount of DKK 20.212497 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,424,994 Price\Range: DKK 0.5 Transaction Features: Rights Offeringお知らせ • Dec 19Stenocare A/S Appoints Rolf Steno to the Board of DirectorsStenocare A/S at its EGM held on December 18, 2024, approved to elect Rolf Steno to the board of directors.お知らせ • Dec 17Stenocare Gains Danish Approval for New Medical Cannabis CBD100 OilStenocare has received approval from the Danish Medicines Agency to start selling a new medical cannabis oil product to Danish patients. The new CBD100 product has a very high concentration of CBD active ingredients (100 mg/ml), and this makes Stenocare the only supplier under the Danish Pilot Programme to offer a CBD100 oil product. The new CBD100 oil product offers additional options for doctors and patients who require significantly higher doses in their treatment. The Stenocare product portfolio now includes four medical cannabis oil products for Danish patients: CBD100, CBD20, THC30, and the mixed THC15/CBD24 oil product, further solidifying Stenocare's position as the leading supplier under the Pilot Programme. On November 26, 2024, Stenocare announced its strategy to transform into a leading trading company for medical cannabis products. By leveraging the strong foundation built since 2017, the company aims to meet diverse patient needs with a broader range of high-quality products. The approval of CBD100 underscores Stenocare's commitment to regulatory excellence, patient-centric innovation, and driving growth in sales.お知らせ • Dec 02STENOCARE A/S Announces Approval of its Innovative Product, Astrum 10-10, for Sale in NorwaySTENOCARE A/S announced the approval of its innovative product, Astrum 10-10, for sale in Norway. This milestone paves the way for more patients to access the benefits of medical cannabis treatment. Astrum 10-10 is expected to become available to patients within the next 30 days. Since 2019, Stenocare has been collaborating with partners to develop and test next-generation medical cannabis oil products, positioning itself as a frontrunner in prescription-based medical cannabis. Stenocare is now ready to introduce its patented product to Norwegian patients. Officially named Astrum 10-10 Oil Stenocare, the product contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle. Innovative Product: The Stenocare Astrum product is based on oil technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation addresses a well-known challenge in medicine dosing by ensuring consistent uptake of active ingredients into the blood. With the Astrum product, Stenocare has successfully completed a pharmacokinetic (PK) study in dogs, documenting two critical parameters in the lymphatic system that can significantly improve bioavailability: Parameter 1 - Uptake in the Blood: According to the pharmacokinetic (PK) study in dogs, Astrum improves blood uptake by a factor of 2.6 compared to a reference MCT-oil product on the market. Low and inconsistent uptake of drugs in the blood across patients is a well-known challenge in the pharmaceutical industry, affecting most medications. This challenge also applies to medical cannabis. When patients use traditional MCT-oil-based medical cannabis, the metabolism often reduces the uptake of cannabinoids in the body. As a result, a highly variable and often limited amount of active ingredients (i.e., cannabinoids) reaches the patient with a therapeutic effect. This creates difficulties in prescribing a consistent dosage to patients. Additionally, blood uptake varies significantly from one individual to another due to biological differences. The new Astrum product helps mitigate these challenges by offering enhanced bioavailability. Parameter 2 - Time to Maximum Effect: According to the pharmacokinetic (PK) study in dogs, the Stenocare Astrum product reduces the time from dosing to maximum effect from 2-4 hours to just 1 hour, providing a more consistent experience for patients. Predictability of uptake and time to maximum effect is crucial when doctors prescribe medical cannabis and when patients use it to treat their symptoms. Time to maximum effect refers to the duration it takes for the medication to reach its highest concentration in the blood after administration. Achieving this maximum effect as quickly as possible is important to help patients manage their symptoms effectively.Board Change • Nov 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Jeppe Petersen was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 05Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr.4.70m (loss narrowed 7.9% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • Nov 05+ 2 more updatesStenocare A/S to Report Q1, 2025 Results on May 08, 2025Stenocare A/S announced that they will report Q1, 2025 results on May 08, 2025お知らせ • Nov 01Stenocare A/S Announces Resignation of Søren Kjær as Board MemberSTENOCARE A/S is changing the Board of Directors. Board member Søren Kjær will leave the board. The Company will nominate Rolf Steno to join the Board at the next general meeting. The Company has accepted the resignation from Board member Søren Kjær and would like to thank him for his contribution to the Board of Directors. The Company will nominate Rolf Steno to join the Board of Directors at the next general meeting. Rolf Steno has a background in sales and international business development.お知らせ • Oct 14Stenocare A/S Updates Earnings Guidance for the Year 2024Stenocare A/S updated earnings guidance for the year 2024. For the year, the company expects gross sales of between DKK 6 million - DKK 8 million is now expected to be DKK 4.5 million for 2024. Based on the Third Quarter actual market performance, the Company is updating guidance for 2024.Reported Earnings • Aug 22Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr.745.3k (down 57% from 2Q 2023). Net loss: kr.3.75m (flat on 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 20Stenocare A/S Updates Sales Guidance for the Year 2024STENOCARE A/S is updating the guidance from November 06, 2023 based on actual market performance from First Quarter and Second Quarter 2024 and the forecast for Third Quarter and Fourth Quarter 2024. The guidance of gross sales of DKK 12 million -DKK 18 million is now expected to be DKK 6 million -DKK 8 million for 2024, which is a growth of +7% compared to 2023. This will also influence the ambition to reach break-even for the last quarter of 2024, which is not realistic with the new sales forecast.お知らせ • May 24Stenocare A/S Launches Next Generation Medical Cannabis Oil Product in AustraliaStenocare A/S announced their new innovative product-line is ready for the market - six months ahead of expectation. The new Astrum brand is an innovative cannabis oil product featuring a patented oil technology that enhances the bioavailability of its active ingredients. This breakthrough allows for higher uptake in the blood, and reduced dosage requirements. The first Astrum product will be launched for patients in Australia during Summer 2024. Ahead of plan: Stenocare has since 2019 been investing with partners to develop and test next generation medical cannabis oil products, that can position Stenocare as a true leader within prescription-based medical cannabis. The new product-line is branded Astrum, and the company has worldwide exclusivity for this patented oil technology. The company is now ready to commercialize the first market during Summer 2024 in Australia. The first product is Astrum 10-10 oil Stenocare, with 10 mg/ml THC and 10 mg/ml CBD. Innovative product: The Stenocare Astrum product is based on an innovative oil technology, that has the potential to increase the cannabinoid's bioavailability in the patient's blood. Thereby, the new product is addressing a well-known challenge with dosing medicine and securing consistent uptake of the active ingredients in the blood. With the Astrum product, Stenocare has completed a pharmacokinetic (PK) study in dogs that documented two important parameters in the lymphatic system that can improve the bioavailability: Parameter 1 - uptake in the blood: According to the PK-study, Astrum improves uptake in the blood with a factor 2.6 - compared to a reference MCT-oil product in the market. Low and inconsistent uptake of the drug in the blood across patients is a well-known challenge in the pharma industry, that applies to most drugs. This also applies to medical cannabis. Today, when patients are administrating traditional MCT-oil based medical cannabis, the metabolism will reduce the uptake of cannabinoids in the body. This means that a highly variable and often little part of the active ingredients (ie. cannabinoids) are delivered inside the patient with a therapeutic effect. This is creating problems to prescribe a steady dosage of the drug to patients. Also, the uptake in the blood is very different for each individual due to biological differences between patients. The new Astrum product is mitigating these challenges and offering higher bioavailability. Parameter 2 - time to max effect: According to the PK-study, the Stenocare Astrum product improves time from dosing to max effect from 2-4 hours to just 1 hour, and offer's a more uniform experience. Predictability of uptake and time to max effect is important when doctors prescribe medical cannabis and when patients use it to treat their symptoms. The time to max effect is the duration of time it takes to reach maximum concentration of the drug in the blood after dosing the drug to the individual. Reaching the maximum as fast as possible is important to help patients manage their symptoms. Commercializing the next generation product: The Stenocare Astrum product is the next generation product, that offers better predictability and uniformity for prescribers and for patients. The new product is protected with a patent and Stenocare is the first company to launch a prescription-based medical cannabis oil product with a lymphatic targeting technology. The commercial stage is now ready to begin, and Stenocare will work with their local partners in Australia to educate prescribers and collect feedback from the market. Stenocare also has the ambition to launch the new product in several additional markets and hope the next commercial launch will happen during second half of 2024 - pending regulatory approvals from the local medicine agency. Path from development to market launch: The findings from the PK-study was announced on September 20, 2022 - which described the potential of the Astrum oil technology. Then Stenocare announced on June 2, 2023 - that an experienced manufacturer was found to produce the new Astrum products. It was expected that the first product would become commercially available during 2024. Since that announcement, the parties have been working hard to source the ingredients and testing production procedures for the new Astrum oil product. The process for having the product approved for sales has successfully been completed, and Stenocare is waiting for the last export certificate that will allow shipment of the new product into Australia. The market launch is expected during Summer 2024.Reported Earnings • May 03First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr.1.15m (up 43% from 1Q 2023). Net loss: kr.3.70m (loss narrowed 17% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.お知らせ • May 03+ 1 more updateStenocare A/S to Report Fiscal Year 2024 Results on Feb 27, 2025Stenocare A/S announced that they will report fiscal year 2024 results on Feb 27, 2025お知らせ • Apr 19Stenocare A/S Announces That the New STENOCARETHC/CBD Medical Cannabis Oil Product Available for Sale in DenmarkStenocare A/S announced, that it had received approval to supply a new THC/CBD medical cannabis oil product under the Danish Pilot Programme. Starting April 18, 2024 the new product is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot. Out of the many suppliers seeking approval to sell their products, Stenocare has been in a clear leadership position from the start of the Pilot in 2018 and is the only supplier of three different medical cannabis oil products under the Pilot. The company has successfully imported the first batch of a new medical cannabis oil product into Denmark. The new product is a combination THC/CBD oil containing 15 mg/ml THC and 24 mg/ml CBD with dosing delivered via an oral syringe. The new product is available starting today via pharmacies and requires a prescription. Strong product portfolio:Stenocare is the first and so far, only supplier of this THC/CBD oil product for the Danish Pilot Programme. With this, Stenocare now once again has the complete portfolio of three medical cannabis oil products (ie. THC30 oil, CBD20 oil and now the THC/CBD oil). With this new product, Stenocare is able to offer the complete range of oil products they successfully sold to patients during 2018 and 2019, that grew the company sales and allowed the Company to reach breakeven in First Quarter 2019. Therefore, having this complete product range for the Danish Pilot Programme is an important element in the 2024 ambitions to once again reach breakeven at the end of the year.お知らせ • Mar 12Stenocare A/S to Deliver New Medical Cannabis Oil Product for Australian PatientsStenocare A/S announced that the company and its partners are now ready to deliver a new medical cannabis oil product for Australian patients. Stenocare announced in November 2023 that the company and its partners had received approval for a new medical cannabis oil product in Australia, set to be available for patients in the first quarter of 2024. This week (March 12), the new product is officially released and made ready for sale to Australian patients. The new product is a "Balanced 25-25 oil" in a 30 ml bottle which has the potential to address a larger target group of patients compared to the first 12.5-12.5 oil product Stenocare introduced for the Australian market.New Risk • Mar 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.10m free cash flow). Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings have declined by 40% per year over the past 5 years. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Revenue is less than US$1m (kr.4.0m revenue, or US$586k). Minor Risk Market cap is less than US$100m (kr.82.6m market cap, or US$12.1m).お知らせ • Feb 27STENOCARE Receives Approval to Sell a New Medical Cannabis Oil Product in DenmarkSTENOCARE A/S announced that it has received approval from The Danish Medicines Agency to sell a new THC/CBD medical cannabis oil product to Danish patients. With this, Stenocare has regained the position as the exclusive (only) provider of all three essential oil products under the Danish Pilot Programme; THC oil, CBD oil, and now also the new THC/CBD oil. This is considered an important milestone for the company towards doubling sales and achieving break-even in 2024. Dedicated to supplying prescription-based medical cannabis products for patient treatment, Stenocare is the only European company with a proven track record in delivering such products across Denmark, Norway, Sweden, the UK, Australia, and Germany. With the new THC/CBD medical cannabis oil product, Stenocare solidifies its position as the pioneer and leading supplier for the Danish Pilot Programme. The new product is called "THC/CBD Olie STENOCARE" and contains 15 mg/mL THC and 24 mg/mL CBD. The new product has been examined by The Danish Medicines Agency for compliance with the Danish Pilot Programme and its strict quality standards. After a very thorough process, the product has now been accepted into the Danish Pilot programme and will be available soon as prescription-based medicine for patients in Denmark pending international import/export certificates and logistics. The three approved Stenocare products are addressing critical therapeutic needs. When looking at data from the Danish Health Data Authority, there is a strong correlation between number of patients and availability of Stenocare oil products. With the new THC/CBD oil introduction, the company is now - once again - able to offer a full product line of medical cannabis oil products, equal to that of 2018-2019. Based on the historic insight it is expected that the number of patients will grow further in the coming year(s). Stenocare has guided that sales may double in 2024 and that break-even is within reach by the end of the year. Having the full product line is a key assumption behind this guidance.Reported Earnings • Feb 23Full year 2023 earnings released: kr.1.18 loss per share (vs kr.1.40 loss in FY 2022)Full year 2023 results: kr.1.18 loss per share. Revenue: kr.3.99m (down 11% from FY 2022). Net loss: kr.17.6m (loss widened 7.8% from FY 2022).お知らせ • Feb 22+ 4 more updatesStenocare A/S to Report Q1, 2024 Results on May 02, 2024Stenocare A/S announced that they will report Q1, 2024 results on May 02, 2024New Risk • Jan 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 59% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.10.0m free cash flow). Earnings have declined by 43% per year over the past 5 years. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Revenue is less than US$1m (kr.5.6m revenue, or US$826k). Market cap is less than US$10m (kr.46.1m market cap, or US$6.82m). Minor Risk Share price has been volatile over the past 3 months (9.2% average weekly change).お知らせ • Nov 23Stenocare A/S Expands Presence with New Medical Cannabis Oil ProductStenocare A/S is experiencing stronger than expected sales (budgets vs. actual) performance in Australia and is now expanding its presence with a new medical cannabis oil product. Off to a good start: Stenocare entered the Australian market in the second half of 2022 with the initial Stenocare-branded Balanced 12.5-12.5 oil product. The response from both doctors and patients has exceeded the expectations. A new product: This positive market launch has prompted Stenocare to introduce its second medical cannabis oil product in Australia. agreements have been signed that will make the new product, a "Balanced 25-25 oil", available to patients in the first quarter of 2024. With these two offerings, the company will expand its reach to doctors and patients and provide choices for both first-time medical cannabis users and experienced patients.Reported Earnings • Nov 10Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr.203.2k (down 31% from 3Q 2022). Net loss: kr.5.11m (loss widened 17% from 3Q 2022).お知らせ • Oct 30Stenocare Ready to Ship Medical Cannabis to German PatientsSTENOCARE A/S announced in June that a Stenocare branded medical cannabis oil product has been approved for sales in Germany, and now the product is ready for sales to German patients. The company is constantly reviewing existing and new market opportunities as the young cannabis industry is evolving around the world. Stenocare has a strong track record of entering new markets and working with local health agencies to have products approved for sales. The first Stenocare branded product is now ready for shipment and sales to German patients. The new Stenocare medical cannabis oil product is called "AD 10-10 STENOCARE Extrakt", which contains 10 mg/mL THC and 10 mg/mL CBD. This completes a thorough approval process with the Federal Institute for Drugs and Medical Devices (BfArM) and logistical planning together with the German partner, ADREXPharma. The first shipment to pharmacies is planned for the week of October 30. Product reimbursement for patients: Germany is the most mature market for medical cannabis in Europe with its large ecosystem of products, suppliers and distributors that serve the approx. 18.000 pharmacies and approx. 230.000 patients. However, only some of the products in the German market are covered by insurance. The new Stenocare product will be eligible for reimbursement by the insurance companies which allows more affordable access to treatment with the new Stenocare product.Reported Earnings • Aug 18Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr.1.72m (up 279% from 2Q 2022). Net loss: kr.3.75m (loss narrowed 22% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 18Stenocare A/S Provides Sales Guidance for the Year 2023Stenocare A/S provided sales guidance for the year 2023. For the year, the company expects sales to be lower than expected, probably in the range of 7.5 to 10.0 mDKK, which is 167% to 222% of sales in 2022. Stenocare still expects to reach an annual revenue run rate by end of 2023 of 15-20 mDKK which will be an important steppingstone ahead of break-even, which is now expected in 2024.お知らせ • Jul 28Stenocare A/S Provides Update on Their Strong Danish Product PipelineStenocare A/S is sharing the plans and work with their strong Danish product pipeline across its four stages from concept to commercialization. Meeting Danish Drug Standards (DLS) the company has a full product program of 2nd generation medical cannabis oil products (stage 3+4), specialized products with unique potency profiles (stage 2) and also 3rd generation product program that can revolutionize the industry (stage 1). Since 2018, Stenocare has been the sole supplier of medical cannabis oil products for the Danish Pilot Programme. The company currently offers two prescription-based oil products (stage 4) for patients: a THC 30 mg/mL product and a CBD 20 mg/mL product. The company continuously analyse market opportunities and feedback from doctors to qualify the product pipeline and deliver on the mission to provide prescription-based medical cannabis products for treatment of patients. Denmark is both the Stenocare home market and a valuable test market for products. This is because the Danish Pilot Program and Danish Medicines Agency are leading the regulatory development for standardization of medical cannabis products, and because highly experienced medical specialists are sharing clinical information that is critical for developing the right product formulations. Having products approved for sales in Denmark has been a gateway for the Stenocare to enter other markets with its product portfolio. Stenocare actively work with their product pipeline to meet needs from medical specialists and offer more choice for patients. The Danish Medicines Agency has a policy of only reviewing one product application at a time (stage 3), and therefore Stenocare carefully manage and prioritize the product pipeline from concept to commercialization in four stages. As more pipeline products reach the commercial stage 4, this is expected to have a significantly positive impact on sales activities in Denmark. Especially the Balanced Oil product in stage 3 is expected to become a hero product - as this product formulation has historically represented +50% of sales volume. The speed of the process towards completion of stage 3 will depend on the Danish Medicines Agency's internal capacity, as they have faced delays in 2023 due to pressure on agency resources, making it challenging for them to meet their own timelines for reviewing applications.Reported Earnings • Jun 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr.807.9k (down 9.9% from 1Q 2022). Net loss: kr.4.46m (loss widened 18% from 1Q 2022).New Risk • Jun 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.16m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 55% per year over the past 5 years. Revenue is less than US$1m (kr.4.5m revenue, or US$654k). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (kr.83.1m market cap, or US$12.1m).お知らせ • Jun 03Stenocare A/S Reports on Significant Progress in Development of Its New Innovative Medical Cannabis ProductStenocare A/S has selecected an international, highly experienced partner to produce a new and innovative medical cannabis oil product, that has the potential to revolutionize the industry and offer patients improved treatment effect. The new product is based on a patented oil technology, that Stenocare has global exclusivity to use for medical cannabis. Absorption and dosage are major problems: A common challenge with mostical medicine as well as in medical cannabis is the accuracy of the dosage uptake in the patients. Generally speaking, the human digestive system breaks down everything that is ingested orally. This results in predictable dosage volume of the medicine to be absorbed in the blood of the patient. Absorption is individual from patient to patient, and therefore prescribing doctors are challenged with defining the right dosage. For the patient this means that there might not be consistency in effect, time to maximum effect, duration of effect and difference between dosing in either fasted or fed state.お知らせ • May 30Stenocare A/S Launches IT-Platform for Online ClinicsStenocare A/S has developed an IT-platform, that enables doctors to launch and operate Online Clinics. The first Online Clinic will be launched in the UK. Stenocare takes prescribing of medical cannabis to the next level: With announcement, Stenocare enables doctors to reach more patients. In short, the new and innovative IT platform enables prescribing doctors, wherever they are, to launch and operate online clinics. This increases a doctor's reach to patients across their geography and facilitates patients' access to trained and experienced doctors and specialists, regardless of where they live within their country. The platform supports doctors in several ways: Administration: patient booking, video consultation, patient journal; knowledge: training, supervision by and ongoing access to the Stenocare medical consultant and specialists; Ownership: Stenocare will transfer ownership to the doctors as the clinic enters more stable operation. Cost efficiency: The platform helps doctors manage total costs and may limit cost per prescription to patients; Compliance: The new IT-platform is GDPR compliant to protect the patient's data. The first to use the new IT-platform is a UK Online pain clinic. The founders are Dr. Ayman Eissa and Stenocare, and it is expected that further doctors will join the clinic. Stenocare has commitment to the transfer of its ownership to the clinic doctors as the clinic reaches a stable operation. The clinic will have a specialty in pain management and treatment with both traditional medicine and medical cannabis. Dr. Ayman Eissa is an experienced pain specialist for +20 years, and a Committee Honorary Secretary within the British Pain Society. It is expected that the new online clinic will go live for UK patients during 2H 2023 - pending regulatory approvals.Reported Earnings • Feb 24Full year 2022 earnings releasedFull year 2022 results: Revenue: kr.4.49m (up 138% from FY 2021). Net loss: kr.16.3m (loss widened 28% from FY 2021).お知らせ • Jan 10Stenocare A/S Provides Sales Guidance for the Year 2023Stenocare A/S provided sales guidance for the year 2023. Stenocare entered three new countries during 2022, and thereby expanded their market presence to five countries with prescription-based medical cannabis oil products approved for sale. With this, Stenocare is in a unique positiveposition to grow its revenue. In the guidance from March 10, 2022, it was expected that majority of sales would materialize during the last part of the year as more markets were added. The guidance was to reach a sales run rate for 2022, that could support a 2023 annual sale of DKK 15-20 million. Based on the Fourth Quarter 2022 performance, Stenocare is on track to deliver on this guidance for 2023.お知らせ • Jan 03Stenocare's New STENOCARE CBD Medical Cannabis Oil Product Is Available in DenmarkSTENOCARE A/S (Stenocare) announced October 14, 2022, that it had received approval to supply a new CBD 20 mg/mL medical cannabis oil product to the Danish Pilot Programme. With this new product, Stenocare is the only supplier of CBD oil products under the Pilot Programme and the new products are officially ready for sales across the entire country. Sales can begin:STENOCARE has completed the import of the new medical cannabis oil product into Denmark. The new product is a CBD oil containing 20 mg/mL with dosing delivered via an oral syringe. The new product is available via pharmacies and requires a prescription from a doctor. Stenocare is the first and so far, only supplier of oil based medical cannabis products for the Danish Pilot Programme with a portfolio of two medical cannabis oil products (ie. THC30 oil and CBD20 oil) from the GMP certified Canadian supplier, AgMEDICA Bioscience.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Jeppe Petersen was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: Net loss: kr.4.35m (loss widened 56% from 3Q 2021).Reported Earnings • Aug 19Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr.4.81m (loss widened 122% from 2Q 2021).Reported Earnings • May 06First quarter 2022 earnings releasedFirst quarter 2022 results: Net loss: kr.3.80m (loss widened 30% from 1Q 2021).Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Jeppe Petersen was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Mar 29Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Nov 29We're Keeping An Eye On Stenocare's (CPH:STENO) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • May 09First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: kr.2.93m (loss widened 3.4% from 1Q 2020).分析記事 • Apr 02Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Dec 23New 90-day high: kr.18.24The company is up 12% from its price of kr.16.30 on 24 September 2020. The Danish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.分析記事 • Dec 18Is Stenocare (CPH:STENO) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Is New 90 Day High Low • Oct 21New 90-day low: kr.15.16The company is down 17% from its price of kr.18.20 on 23 July 2020. The Danish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period.Is New 90 Day High Low • Sep 25New 90-day low: kr.16.30The company is down 11% from its price of kr.18.30 on 26 June 2020. The Danish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period.お知らせ • Jun 16Stenocare A/S has completed a Follow-on Equity Offering in the amount of DKK 44.8092 million.Stenocare A/S has completed a Follow-on Equity Offering in the amount of DKK 44.8092 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,240,460 Price\Range: DKK 20 Transaction Features: Regulation S; Rights Offering株主還元STENODK PharmaceuticalsDK 市場7D-1.3%0.8%0.4%1Y177.1%-33.5%-15.5%株主還元を見る業界別リターン: STENO過去 1 年間で-33.5 % の収益を上げたDanish Pharmaceuticals業界を上回りました。リターン対市場: STENO過去 1 年間で-15.5 % の収益を上げたDanish市場を上回りました。価格変動Is STENO's price volatile compared to industry and market?STENO volatilitySTENO Average Weekly Movement19.3%Pharmaceuticals Industry Average Movement5.8%Market Average Movement4.9%10% most volatile stocks in DK Market9.3%10% least volatile stocks in DK Market2.9%安定した株価: STENOの株価は、 Danish市場と比較して過去 3 か月間で変動しています。時間の経過による変動: STENOの weekly volatility ( 19% ) は過去 1 年間安定していますが、依然としてDanishの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20174Thomas Schnegelsbergstenocare.dkStenocare A/S社は、デンマーク国内および海外の患者向けに、処方箋に基づく医療用大麻製品の栽培、生産、輸入、流通、販売を行っている。THC、THC/CBD、CBDオイル製品を含む医療用大麻オイル製品を提供している。同社は2017年に法人化され、デンマークのランデルスに拠点を置く。もっと見るStenocare A/S 基礎のまとめStenocare の収益と売上を時価総額と比較するとどうか。STENO 基礎統計学時価総額DKK 46.22m収益（TTM）-DKK 855.22k売上高(TTM)DKK 9.24m5.4xP/Sレシオ-58.1xPER（株価収益率STENO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計STENO 損益計算書（TTM）収益DKK 9.24m売上原価DKK 6.26m売上総利益DKK 2.99mその他の費用DKK 3.84m収益-DKK 855.22k直近の収益報告Mar 31, 2026次回決算日Aug 20, 2026一株当たり利益（EPS）-0.02グロス・マージン32.31%純利益率-9.25%有利子負債／自己資本比率16.9%STENO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/28 17:51終値2026/05/28 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Stenocare A/S 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: kr.3.00m (up 284% from 1Q 2025). Net loss: kr.459.0k (loss narrowed 77% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • May 08+ 3 more updatesStenocare A/S to Report Q2, 2026 Results on Aug 20, 2026Stenocare A/S announced that they will report Q2, 2026 results on Aug 20, 2026
お知らせ • Apr 09Stenocare A/S, Annual General Meeting, Apr 29, 2026Stenocare A/S, Annual General Meeting, Apr 29, 2026, at 10:30 Romance Standard Time. Location: lund elmer sandager law firm, kalvebod brygge 39-41, dk-1560 kobenhavn v., Denmark
Reported Earnings • Apr 01Full year 2025 earnings released: kr.0.06 loss per share (vs kr.1.79 loss in FY 2024)Full year 2025 results: kr.0.06 loss per share (improved from kr.1.79 loss in FY 2024). Revenue: kr.7.02m (up 215% from FY 2024). Net loss: kr.2.39m (loss narrowed 93% from FY 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 28Full year 2025 earnings released: kr.0.063 loss per share (vs kr.1.79 loss in FY 2024)Full year 2025 results: kr.0.063 loss per share (improved from kr.1.79 loss in FY 2024). Revenue: kr.7.02m (up 215% from FY 2024). Net loss: kr.2.39m (loss narrowed 93% from FY 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
New Risk • Dec 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr.62.2m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.3.4m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Revenue is less than US$1m (kr.5.7m revenue, or US$891k). Market cap is less than US$10m (kr.62.2m market cap, or US$9.77m).
Reported Earnings • May 11First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: kr.3.00m (up 284% from 1Q 2025). Net loss: kr.459.0k (loss narrowed 77% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • May 08+ 3 more updatesStenocare A/S to Report Q2, 2026 Results on Aug 20, 2026Stenocare A/S announced that they will report Q2, 2026 results on Aug 20, 2026
お知らせ • Apr 09Stenocare A/S, Annual General Meeting, Apr 29, 2026Stenocare A/S, Annual General Meeting, Apr 29, 2026, at 10:30 Romance Standard Time. Location: lund elmer sandager law firm, kalvebod brygge 39-41, dk-1560 kobenhavn v., Denmark
Reported Earnings • Apr 01Full year 2025 earnings released: kr.0.06 loss per share (vs kr.1.79 loss in FY 2024)Full year 2025 results: kr.0.06 loss per share (improved from kr.1.79 loss in FY 2024). Revenue: kr.7.02m (up 215% from FY 2024). Net loss: kr.2.39m (loss narrowed 93% from FY 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 28Full year 2025 earnings released: kr.0.063 loss per share (vs kr.1.79 loss in FY 2024)Full year 2025 results: kr.0.063 loss per share (improved from kr.1.79 loss in FY 2024). Revenue: kr.7.02m (up 215% from FY 2024). Net loss: kr.2.39m (loss narrowed 93% from FY 2024). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
New Risk • Dec 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr.62.2m (US$9.77m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.3.4m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (116% increase in shares outstanding). Revenue is less than US$1m (kr.5.7m revenue, or US$891k). Market cap is less than US$10m (kr.62.2m market cap, or US$9.77m).
Reported Earnings • Oct 23Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr.103.3k (loss narrowed 98% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 27Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: kr.1.72m (up 131% from 2Q 2024). Net loss: kr.145.6k (loss narrowed 96% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
お知らせ • May 16Stenocare A/S Appoints Henrik Elbæk Pedersen as Board MemberStenocare A/S announced that at the AGM held on 15 May 2025 approved election of Henrik Elbæk Pedersen as a new board member. Hereafter, the board of directors consist of Marianne Wier (chairman), Jeppe Bo Petersen, Rolf Steno Petersen, Søren Melsing Frederiksen and Henrik Elbæk Pedersen.
New Risk • May 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 110% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.7.0m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (110% increase in shares outstanding). Revenue is less than US$1m (kr.1.9m revenue, or US$279k). Market cap is less than US$10m (kr.13.8m market cap, or US$2.07m).
Reported Earnings • May 09First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: kr.781.7k (down 32% from 1Q 2024). Net loss: kr.1.99m (loss narrowed 46% from 1Q 2024).
お知らせ • Apr 23Stenocare A/S, Annual General Meeting, May 15, 2025Stenocare A/S, Annual General Meeting, May 15, 2025, at 10:00 Romance Standard Time. Location: lund elmer sandager law firm, kalvebod brygge 39-41, dk-1560, kobenhavn v, Denmark
お知らせ • Apr 03STENOCARE A/S and Its Local Partner Secure Approval for the Reimbursement of the Innovative Astrum 10-10 Product in GermanySTENOCARE A/S and its local partner have successfully secured approval for the reimbursement of the innovative ASTRUM 10-10 product by major German health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible for 100% reimbursement when treated with ASTRUM 10-10. The ASTRUM 10-10 oil product was made available to German patients in January 2025 and has now been approved for 100% reimbursement by two leading German health insurance providers, Techniker Krankenkasse and AOK Rheinland. Germany represents the largest medical cannabis market in Europe. Industry analysts, including Prohibition Partners, forecast a 275% growth by 2027, with total sales expected to reach EUR 1 billion. Stenocare's new and innovative medical cannabis oil product is officially named Astrum 10-10 Ext Stenocare. It contains 10 mg/ml of THC and 10 mg/ml of CBD, supplied in a 30 ml bottle. The PNZ is 15192488 and the German supplier is ADREXpharma GmbH. The Stenocare Astrum product is based on advanced oil technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation addresses a common challenge in medicinal dosing by promoting the consistent absorption of active ingredients. Stenocare has conducted a successful pharmacokinetic (PK) study in dogs, which demonstrated two key improvements in the lymphatic system that can significantly enhance bioavailability: A significant increase in cannabinoid uptake into the bloodstream, improving therapeutic effect and a faster, more uniform absorption across patients.
Reported Earnings • Apr 02Full year 2024 earnings released: kr.1.79 loss per share (vs kr.1.26 loss in FY 2023)Full year 2024 results: kr.1.79 loss per share (further deteriorated from kr.1.26 loss in FY 2023). Revenue: kr.2.23m (down 41% from FY 2023). Net loss: kr.34.5m (loss widened 96% from FY 2023).
お知らせ • Mar 31Stenocare Begins Sales of New CBD100 Oil Product in DenmarkSTENOCARE A/S has delivered the first shipment of its new CBD100 Oil product to the Danish market. With this new medical cannabis oil product, Stenocare now offers four different prescription-based medical cannabis oil products to Danish patients, making it the leading provider of oil products in the Danish Pilot Programme. The company already offers a THC30 Oil product, a CBD20 Oil product, and a THC/CBD Oil product. Now, Stenocare is adding its CBD100 Oil product to the portfolio-providing patients with even more treatment options and further strengthening its position as a leading provider of medical cannabis oil products in the Pilot Programme. The new product is named CBD100 Oil Stenocare, and it contains 100 mg/ml CBD and 5 mg/ml THC in a 30 ml bottle. The first shipment of CBD100 has just been delivered in Denmark and is now available to patients across the country.
Reported Earnings • Feb 28Full year 2024 earnings released: kr.1.73 loss per share (vs kr.1.26 loss in FY 2023)Full year 2024 results: kr.1.73 loss per share (further deteriorated from kr.1.26 loss in FY 2023). Revenue: kr.2.23m (down 44% from FY 2023). Net loss: kr.34.5m (loss widened 96% from FY 2023).
お知らせ • Feb 14Stenocare A/S Announces the Innovative Astrum 10-10 Product Is Now Available for Australian PatientsStenocare A/S reach an important milestone with ASTRUM 10-10, that is now ready for sales to Australian patients. The innovative and patented medical cannabis oil product, ASTRUM 10-10 has the potential to improve uptake in the blood and thereby improve efficacy of the treatment. Stenocare's new innovative medical cannabis oil product named Astrum 10-10 has been approved for sales in Australia and is now ready for patient's treatment. Officially named "Astrum 10-10 Oil Stenocare," the product contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle. The Stenocare Astrum product is based on cutting-edge oil technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation addresses a well-known challenge in medicine dosing by ensuring consistent uptake of active ingredients into the blood. With the Astrum product, Stenocare has successfully completed a pharmacokinetic (PK) study in dogs, documenting two critical parameters in the lymphatic system that can significantly improve bioavailability: Uptake in the Blood: According to the pharmacokinetic (PK) study in dogs, Astrum improves blood uptake by a factor of 2.6 compared to a reference MCT-oil product on the market. Low and inconsistent uptake of drugs in the blood across patients is a well-known challenge in the pharmaceutical industry, affecting most medications. This challenge also applies to medical cannabis. When patients use traditional MCT-oil-based medical cannabis, the metabolism often reduces the uptake of cannabinoids in the body. As a result, a highly variable and often limited amount of active ingredients (i.e., cannabinoids) reaches the patient with a therapeutic effect. This creates difficulties in prescribing a consistent dosage to patients. Additionally, blood uptake varies significantly from one individual to another due to biological differences. The new Astrum product helps mitigate these challenges by offering enhanced bioavailability.
お知らせ • Jan 22Stenocare A/S has completed a Follow-on Equity Offering in the amount of DKK 9.095624 million.Stenocare A/S has completed a Follow-on Equity Offering in the amount of DKK 9.095624 million. Security Name: Shares Security Type: Common Stock Securities Offered: 18,191,248 Price\Range: DKK 0.5 Transaction Features: Rights Offering
お知らせ • Jan 03STENOCARE's Innovative ASTRUM 10-10 Product Now Available for Norwegian PatientsStenocare announced on December 2, 2024, that the new innovative medical cannabis oil product, named Astrum 10-10, has been approved for sale in Norway. At the end of December, the first shipment of this product arrived in Norway and is ready for patients' treatment. Officially named 'Astrum 10-10 Oil Stenocare,' the product contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle. The Stenocare Astrum product is based on cutting-edge oil technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation addresses a well-known challenge in medicine dosing by ensuring consistent uptake of active ingredients into the blood. With the Astrum product, Stenocare has successfully completed a pharmacokinetic (PK) study in dogs, documenting two critical parameters in the lymphatic system that can significantly improve bioavailability: Parameter 1 - Uptake in the Blood: According to the pharmacokinetic (PK) study in dogs, Astrum improves blood uptake by a factor of 2.6 compared to a reference MCT-oil product on the market. Low and inconsistent uptake of drugs in the blood across patients is a well-known challenge in the pharmaceutical industry, affecting most medications. This challenge also applies to medical cannabis. When patients use traditional MCT-oil-based medical cannabis, the metabolism often reduces the uptake of cannabinoids in the body. As a result, a highly variable and often limited amount of active ingredients (i.e., cannabinoids) reaches the patient with a therapeutic effect. This creates difficulties in prescribing a consistent dosage to patients. Additionally, blood uptake varies significantly from one individual to another due to biological differences. The new Astrum product helps mitigate these challenges by offering enhanced bioavailability. Parameter 2 - Time to Maximum Effect: According to the PK- study in dogs, the Stenocare Astrum product reduces the time from dosing to maximum effect from 2-4 hours to just 1 hour, providing a more consistent experience for patients. Predictability of uptake and time to maximum effect is crucial when doctors prescribe medical cannabis and when patients use it to treat their symptoms. Time to maximum effect refers to the duration it takes for the medication to reach its highest concentration in the blood after administration. Achieving this maximum effect as quickly as possible is important to help patients manage their symptoms effectively.
お知らせ • Dec 20Stenocare A/S has filed a Follow-on Equity Offering in the amount of DKK 20.212497 million.Stenocare A/S has filed a Follow-on Equity Offering in the amount of DKK 20.212497 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,424,994 Price\Range: DKK 0.5 Transaction Features: Rights Offering
お知らせ • Dec 19Stenocare A/S Appoints Rolf Steno to the Board of DirectorsStenocare A/S at its EGM held on December 18, 2024, approved to elect Rolf Steno to the board of directors.
お知らせ • Dec 17Stenocare Gains Danish Approval for New Medical Cannabis CBD100 OilStenocare has received approval from the Danish Medicines Agency to start selling a new medical cannabis oil product to Danish patients. The new CBD100 product has a very high concentration of CBD active ingredients (100 mg/ml), and this makes Stenocare the only supplier under the Danish Pilot Programme to offer a CBD100 oil product. The new CBD100 oil product offers additional options for doctors and patients who require significantly higher doses in their treatment. The Stenocare product portfolio now includes four medical cannabis oil products for Danish patients: CBD100, CBD20, THC30, and the mixed THC15/CBD24 oil product, further solidifying Stenocare's position as the leading supplier under the Pilot Programme. On November 26, 2024, Stenocare announced its strategy to transform into a leading trading company for medical cannabis products. By leveraging the strong foundation built since 2017, the company aims to meet diverse patient needs with a broader range of high-quality products. The approval of CBD100 underscores Stenocare's commitment to regulatory excellence, patient-centric innovation, and driving growth in sales.
お知らせ • Dec 02STENOCARE A/S Announces Approval of its Innovative Product, Astrum 10-10, for Sale in NorwaySTENOCARE A/S announced the approval of its innovative product, Astrum 10-10, for sale in Norway. This milestone paves the way for more patients to access the benefits of medical cannabis treatment. Astrum 10-10 is expected to become available to patients within the next 30 days. Since 2019, Stenocare has been collaborating with partners to develop and test next-generation medical cannabis oil products, positioning itself as a frontrunner in prescription-based medical cannabis. Stenocare is now ready to introduce its patented product to Norwegian patients. Officially named Astrum 10-10 Oil Stenocare, the product contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle. Innovative Product: The Stenocare Astrum product is based on oil technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation addresses a well-known challenge in medicine dosing by ensuring consistent uptake of active ingredients into the blood. With the Astrum product, Stenocare has successfully completed a pharmacokinetic (PK) study in dogs, documenting two critical parameters in the lymphatic system that can significantly improve bioavailability: Parameter 1 - Uptake in the Blood: According to the pharmacokinetic (PK) study in dogs, Astrum improves blood uptake by a factor of 2.6 compared to a reference MCT-oil product on the market. Low and inconsistent uptake of drugs in the blood across patients is a well-known challenge in the pharmaceutical industry, affecting most medications. This challenge also applies to medical cannabis. When patients use traditional MCT-oil-based medical cannabis, the metabolism often reduces the uptake of cannabinoids in the body. As a result, a highly variable and often limited amount of active ingredients (i.e., cannabinoids) reaches the patient with a therapeutic effect. This creates difficulties in prescribing a consistent dosage to patients. Additionally, blood uptake varies significantly from one individual to another due to biological differences. The new Astrum product helps mitigate these challenges by offering enhanced bioavailability. Parameter 2 - Time to Maximum Effect: According to the pharmacokinetic (PK) study in dogs, the Stenocare Astrum product reduces the time from dosing to maximum effect from 2-4 hours to just 1 hour, providing a more consistent experience for patients. Predictability of uptake and time to maximum effect is crucial when doctors prescribe medical cannabis and when patients use it to treat their symptoms. Time to maximum effect refers to the duration it takes for the medication to reach its highest concentration in the blood after administration. Achieving this maximum effect as quickly as possible is important to help patients manage their symptoms effectively.
Board Change • Nov 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Jeppe Petersen was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 05Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr.4.70m (loss narrowed 7.9% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • Nov 05+ 2 more updatesStenocare A/S to Report Q1, 2025 Results on May 08, 2025Stenocare A/S announced that they will report Q1, 2025 results on May 08, 2025
お知らせ • Nov 01Stenocare A/S Announces Resignation of Søren Kjær as Board MemberSTENOCARE A/S is changing the Board of Directors. Board member Søren Kjær will leave the board. The Company will nominate Rolf Steno to join the Board at the next general meeting. The Company has accepted the resignation from Board member Søren Kjær and would like to thank him for his contribution to the Board of Directors. The Company will nominate Rolf Steno to join the Board of Directors at the next general meeting. Rolf Steno has a background in sales and international business development.
お知らせ • Oct 14Stenocare A/S Updates Earnings Guidance for the Year 2024Stenocare A/S updated earnings guidance for the year 2024. For the year, the company expects gross sales of between DKK 6 million - DKK 8 million is now expected to be DKK 4.5 million for 2024. Based on the Third Quarter actual market performance, the Company is updating guidance for 2024.
Reported Earnings • Aug 22Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr.745.3k (down 57% from 2Q 2023). Net loss: kr.3.75m (flat on 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 20Stenocare A/S Updates Sales Guidance for the Year 2024STENOCARE A/S is updating the guidance from November 06, 2023 based on actual market performance from First Quarter and Second Quarter 2024 and the forecast for Third Quarter and Fourth Quarter 2024. The guidance of gross sales of DKK 12 million -DKK 18 million is now expected to be DKK 6 million -DKK 8 million for 2024, which is a growth of +7% compared to 2023. This will also influence the ambition to reach break-even for the last quarter of 2024, which is not realistic with the new sales forecast.
お知らせ • May 24Stenocare A/S Launches Next Generation Medical Cannabis Oil Product in AustraliaStenocare A/S announced their new innovative product-line is ready for the market - six months ahead of expectation. The new Astrum brand is an innovative cannabis oil product featuring a patented oil technology that enhances the bioavailability of its active ingredients. This breakthrough allows for higher uptake in the blood, and reduced dosage requirements. The first Astrum product will be launched for patients in Australia during Summer 2024. Ahead of plan: Stenocare has since 2019 been investing with partners to develop and test next generation medical cannabis oil products, that can position Stenocare as a true leader within prescription-based medical cannabis. The new product-line is branded Astrum, and the company has worldwide exclusivity for this patented oil technology. The company is now ready to commercialize the first market during Summer 2024 in Australia. The first product is Astrum 10-10 oil Stenocare, with 10 mg/ml THC and 10 mg/ml CBD. Innovative product: The Stenocare Astrum product is based on an innovative oil technology, that has the potential to increase the cannabinoid's bioavailability in the patient's blood. Thereby, the new product is addressing a well-known challenge with dosing medicine and securing consistent uptake of the active ingredients in the blood. With the Astrum product, Stenocare has completed a pharmacokinetic (PK) study in dogs that documented two important parameters in the lymphatic system that can improve the bioavailability: Parameter 1 - uptake in the blood: According to the PK-study, Astrum improves uptake in the blood with a factor 2.6 - compared to a reference MCT-oil product in the market. Low and inconsistent uptake of the drug in the blood across patients is a well-known challenge in the pharma industry, that applies to most drugs. This also applies to medical cannabis. Today, when patients are administrating traditional MCT-oil based medical cannabis, the metabolism will reduce the uptake of cannabinoids in the body. This means that a highly variable and often little part of the active ingredients (ie. cannabinoids) are delivered inside the patient with a therapeutic effect. This is creating problems to prescribe a steady dosage of the drug to patients. Also, the uptake in the blood is very different for each individual due to biological differences between patients. The new Astrum product is mitigating these challenges and offering higher bioavailability. Parameter 2 - time to max effect: According to the PK-study, the Stenocare Astrum product improves time from dosing to max effect from 2-4 hours to just 1 hour, and offer's a more uniform experience. Predictability of uptake and time to max effect is important when doctors prescribe medical cannabis and when patients use it to treat their symptoms. The time to max effect is the duration of time it takes to reach maximum concentration of the drug in the blood after dosing the drug to the individual. Reaching the maximum as fast as possible is important to help patients manage their symptoms. Commercializing the next generation product: The Stenocare Astrum product is the next generation product, that offers better predictability and uniformity for prescribers and for patients. The new product is protected with a patent and Stenocare is the first company to launch a prescription-based medical cannabis oil product with a lymphatic targeting technology. The commercial stage is now ready to begin, and Stenocare will work with their local partners in Australia to educate prescribers and collect feedback from the market. Stenocare also has the ambition to launch the new product in several additional markets and hope the next commercial launch will happen during second half of 2024 - pending regulatory approvals from the local medicine agency. Path from development to market launch: The findings from the PK-study was announced on September 20, 2022 - which described the potential of the Astrum oil technology. Then Stenocare announced on June 2, 2023 - that an experienced manufacturer was found to produce the new Astrum products. It was expected that the first product would become commercially available during 2024. Since that announcement, the parties have been working hard to source the ingredients and testing production procedures for the new Astrum oil product. The process for having the product approved for sales has successfully been completed, and Stenocare is waiting for the last export certificate that will allow shipment of the new product into Australia. The market launch is expected during Summer 2024.
Reported Earnings • May 03First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr.1.15m (up 43% from 1Q 2023). Net loss: kr.3.70m (loss narrowed 17% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.
お知らせ • May 03+ 1 more updateStenocare A/S to Report Fiscal Year 2024 Results on Feb 27, 2025Stenocare A/S announced that they will report fiscal year 2024 results on Feb 27, 2025
お知らせ • Apr 19Stenocare A/S Announces That the New STENOCARETHC/CBD Medical Cannabis Oil Product Available for Sale in DenmarkStenocare A/S announced, that it had received approval to supply a new THC/CBD medical cannabis oil product under the Danish Pilot Programme. Starting April 18, 2024 the new product is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot. Out of the many suppliers seeking approval to sell their products, Stenocare has been in a clear leadership position from the start of the Pilot in 2018 and is the only supplier of three different medical cannabis oil products under the Pilot. The company has successfully imported the first batch of a new medical cannabis oil product into Denmark. The new product is a combination THC/CBD oil containing 15 mg/ml THC and 24 mg/ml CBD with dosing delivered via an oral syringe. The new product is available starting today via pharmacies and requires a prescription. Strong product portfolio:Stenocare is the first and so far, only supplier of this THC/CBD oil product for the Danish Pilot Programme. With this, Stenocare now once again has the complete portfolio of three medical cannabis oil products (ie. THC30 oil, CBD20 oil and now the THC/CBD oil). With this new product, Stenocare is able to offer the complete range of oil products they successfully sold to patients during 2018 and 2019, that grew the company sales and allowed the Company to reach breakeven in First Quarter 2019. Therefore, having this complete product range for the Danish Pilot Programme is an important element in the 2024 ambitions to once again reach breakeven at the end of the year.
お知らせ • Mar 12Stenocare A/S to Deliver New Medical Cannabis Oil Product for Australian PatientsStenocare A/S announced that the company and its partners are now ready to deliver a new medical cannabis oil product for Australian patients. Stenocare announced in November 2023 that the company and its partners had received approval for a new medical cannabis oil product in Australia, set to be available for patients in the first quarter of 2024. This week (March 12), the new product is officially released and made ready for sale to Australian patients. The new product is a "Balanced 25-25 oil" in a 30 ml bottle which has the potential to address a larger target group of patients compared to the first 12.5-12.5 oil product Stenocare introduced for the Australian market.
New Risk • Mar 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.10m free cash flow). Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings have declined by 40% per year over the past 5 years. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Revenue is less than US$1m (kr.4.0m revenue, or US$586k). Minor Risk Market cap is less than US$100m (kr.82.6m market cap, or US$12.1m).
お知らせ • Feb 27STENOCARE Receives Approval to Sell a New Medical Cannabis Oil Product in DenmarkSTENOCARE A/S announced that it has received approval from The Danish Medicines Agency to sell a new THC/CBD medical cannabis oil product to Danish patients. With this, Stenocare has regained the position as the exclusive (only) provider of all three essential oil products under the Danish Pilot Programme; THC oil, CBD oil, and now also the new THC/CBD oil. This is considered an important milestone for the company towards doubling sales and achieving break-even in 2024. Dedicated to supplying prescription-based medical cannabis products for patient treatment, Stenocare is the only European company with a proven track record in delivering such products across Denmark, Norway, Sweden, the UK, Australia, and Germany. With the new THC/CBD medical cannabis oil product, Stenocare solidifies its position as the pioneer and leading supplier for the Danish Pilot Programme. The new product is called "THC/CBD Olie STENOCARE" and contains 15 mg/mL THC and 24 mg/mL CBD. The new product has been examined by The Danish Medicines Agency for compliance with the Danish Pilot Programme and its strict quality standards. After a very thorough process, the product has now been accepted into the Danish Pilot programme and will be available soon as prescription-based medicine for patients in Denmark pending international import/export certificates and logistics. The three approved Stenocare products are addressing critical therapeutic needs. When looking at data from the Danish Health Data Authority, there is a strong correlation between number of patients and availability of Stenocare oil products. With the new THC/CBD oil introduction, the company is now - once again - able to offer a full product line of medical cannabis oil products, equal to that of 2018-2019. Based on the historic insight it is expected that the number of patients will grow further in the coming year(s). Stenocare has guided that sales may double in 2024 and that break-even is within reach by the end of the year. Having the full product line is a key assumption behind this guidance.
Reported Earnings • Feb 23Full year 2023 earnings released: kr.1.18 loss per share (vs kr.1.40 loss in FY 2022)Full year 2023 results: kr.1.18 loss per share. Revenue: kr.3.99m (down 11% from FY 2022). Net loss: kr.17.6m (loss widened 7.8% from FY 2022).
お知らせ • Feb 22+ 4 more updatesStenocare A/S to Report Q1, 2024 Results on May 02, 2024Stenocare A/S announced that they will report Q1, 2024 results on May 02, 2024
New Risk • Jan 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 59% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.10.0m free cash flow). Earnings have declined by 43% per year over the past 5 years. Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Revenue is less than US$1m (kr.5.6m revenue, or US$826k). Market cap is less than US$10m (kr.46.1m market cap, or US$6.82m). Minor Risk Share price has been volatile over the past 3 months (9.2% average weekly change).
お知らせ • Nov 23Stenocare A/S Expands Presence with New Medical Cannabis Oil ProductStenocare A/S is experiencing stronger than expected sales (budgets vs. actual) performance in Australia and is now expanding its presence with a new medical cannabis oil product. Off to a good start: Stenocare entered the Australian market in the second half of 2022 with the initial Stenocare-branded Balanced 12.5-12.5 oil product. The response from both doctors and patients has exceeded the expectations. A new product: This positive market launch has prompted Stenocare to introduce its second medical cannabis oil product in Australia. agreements have been signed that will make the new product, a "Balanced 25-25 oil", available to patients in the first quarter of 2024. With these two offerings, the company will expand its reach to doctors and patients and provide choices for both first-time medical cannabis users and experienced patients.
Reported Earnings • Nov 10Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr.203.2k (down 31% from 3Q 2022). Net loss: kr.5.11m (loss widened 17% from 3Q 2022).
お知らせ • Oct 30Stenocare Ready to Ship Medical Cannabis to German PatientsSTENOCARE A/S announced in June that a Stenocare branded medical cannabis oil product has been approved for sales in Germany, and now the product is ready for sales to German patients. The company is constantly reviewing existing and new market opportunities as the young cannabis industry is evolving around the world. Stenocare has a strong track record of entering new markets and working with local health agencies to have products approved for sales. The first Stenocare branded product is now ready for shipment and sales to German patients. The new Stenocare medical cannabis oil product is called "AD 10-10 STENOCARE Extrakt", which contains 10 mg/mL THC and 10 mg/mL CBD. This completes a thorough approval process with the Federal Institute for Drugs and Medical Devices (BfArM) and logistical planning together with the German partner, ADREXPharma. The first shipment to pharmacies is planned for the week of October 30. Product reimbursement for patients: Germany is the most mature market for medical cannabis in Europe with its large ecosystem of products, suppliers and distributors that serve the approx. 18.000 pharmacies and approx. 230.000 patients. However, only some of the products in the German market are covered by insurance. The new Stenocare product will be eligible for reimbursement by the insurance companies which allows more affordable access to treatment with the new Stenocare product.
Reported Earnings • Aug 18Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr.1.72m (up 279% from 2Q 2022). Net loss: kr.3.75m (loss narrowed 22% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 18Stenocare A/S Provides Sales Guidance for the Year 2023Stenocare A/S provided sales guidance for the year 2023. For the year, the company expects sales to be lower than expected, probably in the range of 7.5 to 10.0 mDKK, which is 167% to 222% of sales in 2022. Stenocare still expects to reach an annual revenue run rate by end of 2023 of 15-20 mDKK which will be an important steppingstone ahead of break-even, which is now expected in 2024.
お知らせ • Jul 28Stenocare A/S Provides Update on Their Strong Danish Product PipelineStenocare A/S is sharing the plans and work with their strong Danish product pipeline across its four stages from concept to commercialization. Meeting Danish Drug Standards (DLS) the company has a full product program of 2nd generation medical cannabis oil products (stage 3+4), specialized products with unique potency profiles (stage 2) and also 3rd generation product program that can revolutionize the industry (stage 1). Since 2018, Stenocare has been the sole supplier of medical cannabis oil products for the Danish Pilot Programme. The company currently offers two prescription-based oil products (stage 4) for patients: a THC 30 mg/mL product and a CBD 20 mg/mL product. The company continuously analyse market opportunities and feedback from doctors to qualify the product pipeline and deliver on the mission to provide prescription-based medical cannabis products for treatment of patients. Denmark is both the Stenocare home market and a valuable test market for products. This is because the Danish Pilot Program and Danish Medicines Agency are leading the regulatory development for standardization of medical cannabis products, and because highly experienced medical specialists are sharing clinical information that is critical for developing the right product formulations. Having products approved for sales in Denmark has been a gateway for the Stenocare to enter other markets with its product portfolio. Stenocare actively work with their product pipeline to meet needs from medical specialists and offer more choice for patients. The Danish Medicines Agency has a policy of only reviewing one product application at a time (stage 3), and therefore Stenocare carefully manage and prioritize the product pipeline from concept to commercialization in four stages. As more pipeline products reach the commercial stage 4, this is expected to have a significantly positive impact on sales activities in Denmark. Especially the Balanced Oil product in stage 3 is expected to become a hero product - as this product formulation has historically represented +50% of sales volume. The speed of the process towards completion of stage 3 will depend on the Danish Medicines Agency's internal capacity, as they have faced delays in 2023 due to pressure on agency resources, making it challenging for them to meet their own timelines for reviewing applications.
Reported Earnings • Jun 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr.807.9k (down 9.9% from 1Q 2022). Net loss: kr.4.46m (loss widened 18% from 1Q 2022).
New Risk • Jun 15New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr.16m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 55% per year over the past 5 years. Revenue is less than US$1m (kr.4.5m revenue, or US$654k). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (kr.83.1m market cap, or US$12.1m).
お知らせ • Jun 03Stenocare A/S Reports on Significant Progress in Development of Its New Innovative Medical Cannabis ProductStenocare A/S has selecected an international, highly experienced partner to produce a new and innovative medical cannabis oil product, that has the potential to revolutionize the industry and offer patients improved treatment effect. The new product is based on a patented oil technology, that Stenocare has global exclusivity to use for medical cannabis. Absorption and dosage are major problems: A common challenge with mostical medicine as well as in medical cannabis is the accuracy of the dosage uptake in the patients. Generally speaking, the human digestive system breaks down everything that is ingested orally. This results in predictable dosage volume of the medicine to be absorbed in the blood of the patient. Absorption is individual from patient to patient, and therefore prescribing doctors are challenged with defining the right dosage. For the patient this means that there might not be consistency in effect, time to maximum effect, duration of effect and difference between dosing in either fasted or fed state.
お知らせ • May 30Stenocare A/S Launches IT-Platform for Online ClinicsStenocare A/S has developed an IT-platform, that enables doctors to launch and operate Online Clinics. The first Online Clinic will be launched in the UK. Stenocare takes prescribing of medical cannabis to the next level: With announcement, Stenocare enables doctors to reach more patients. In short, the new and innovative IT platform enables prescribing doctors, wherever they are, to launch and operate online clinics. This increases a doctor's reach to patients across their geography and facilitates patients' access to trained and experienced doctors and specialists, regardless of where they live within their country. The platform supports doctors in several ways: Administration: patient booking, video consultation, patient journal; knowledge: training, supervision by and ongoing access to the Stenocare medical consultant and specialists; Ownership: Stenocare will transfer ownership to the doctors as the clinic enters more stable operation. Cost efficiency: The platform helps doctors manage total costs and may limit cost per prescription to patients; Compliance: The new IT-platform is GDPR compliant to protect the patient's data. The first to use the new IT-platform is a UK Online pain clinic. The founders are Dr. Ayman Eissa and Stenocare, and it is expected that further doctors will join the clinic. Stenocare has commitment to the transfer of its ownership to the clinic doctors as the clinic reaches a stable operation. The clinic will have a specialty in pain management and treatment with both traditional medicine and medical cannabis. Dr. Ayman Eissa is an experienced pain specialist for +20 years, and a Committee Honorary Secretary within the British Pain Society. It is expected that the new online clinic will go live for UK patients during 2H 2023 - pending regulatory approvals.
Reported Earnings • Feb 24Full year 2022 earnings releasedFull year 2022 results: Revenue: kr.4.49m (up 138% from FY 2021). Net loss: kr.16.3m (loss widened 28% from FY 2021).
お知らせ • Jan 10Stenocare A/S Provides Sales Guidance for the Year 2023Stenocare A/S provided sales guidance for the year 2023. Stenocare entered three new countries during 2022, and thereby expanded their market presence to five countries with prescription-based medical cannabis oil products approved for sale. With this, Stenocare is in a unique positiveposition to grow its revenue. In the guidance from March 10, 2022, it was expected that majority of sales would materialize during the last part of the year as more markets were added. The guidance was to reach a sales run rate for 2022, that could support a 2023 annual sale of DKK 15-20 million. Based on the Fourth Quarter 2022 performance, Stenocare is on track to deliver on this guidance for 2023.
お知らせ • Jan 03Stenocare's New STENOCARE CBD Medical Cannabis Oil Product Is Available in DenmarkSTENOCARE A/S (Stenocare) announced October 14, 2022, that it had received approval to supply a new CBD 20 mg/mL medical cannabis oil product to the Danish Pilot Programme. With this new product, Stenocare is the only supplier of CBD oil products under the Pilot Programme and the new products are officially ready for sales across the entire country. Sales can begin:STENOCARE has completed the import of the new medical cannabis oil product into Denmark. The new product is a CBD oil containing 20 mg/mL with dosing delivered via an oral syringe. The new product is available via pharmacies and requires a prescription from a doctor. Stenocare is the first and so far, only supplier of oil based medical cannabis products for the Danish Pilot Programme with a portfolio of two medical cannabis oil products (ie. THC30 oil and CBD20 oil) from the GMP certified Canadian supplier, AgMEDICA Bioscience.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Jeppe Petersen was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 11Third quarter 2022 earnings releasedThird quarter 2022 results: Net loss: kr.4.35m (loss widened 56% from 3Q 2021).
Reported Earnings • Aug 19Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr.4.81m (loss widened 122% from 2Q 2021).
Reported Earnings • May 06First quarter 2022 earnings releasedFirst quarter 2022 results: Net loss: kr.3.80m (loss widened 30% from 1Q 2021).
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Independent Director Jeppe Petersen was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Mar 29Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
分析記事 • Nov 29We're Keeping An Eye On Stenocare's (CPH:STENO) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • May 09First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: kr.2.93m (loss widened 3.4% from 1Q 2020).
分析記事 • Apr 02Is Stenocare (CPH:STENO) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Dec 23New 90-day high: kr.18.24The company is up 12% from its price of kr.16.30 on 24 September 2020. The Danish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.
分析記事 • Dec 18Is Stenocare (CPH:STENO) In A Good Position To Invest In Growth?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Is New 90 Day High Low • Oct 21New 90-day low: kr.15.16The company is down 17% from its price of kr.18.20 on 23 July 2020. The Danish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period.
Is New 90 Day High Low • Sep 25New 90-day low: kr.16.30The company is down 11% from its price of kr.18.30 on 26 June 2020. The Danish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
お知らせ • Jun 16Stenocare A/S has completed a Follow-on Equity Offering in the amount of DKK 44.8092 million.Stenocare A/S has completed a Follow-on Equity Offering in the amount of DKK 44.8092 million. Security Name: Shares Security Type: Common Stock Securities Offered: 2,240,460 Price\Range: DKK 20 Transaction Features: Regulation S; Rights Offering
